Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity

Ian A. Cree, Christian M. Kurbacher, Michael Untch, Lesley A. Sutherland, Elizabeth M. Hunter, Andrea M. C. Subedi, Elizabeth A. James, John A. Dewar, Paul E. Preece, Peter E. Andreotti, Howard W. Bruckner

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which fails to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from a newly developed tumor chemosensitivity assay (TCA) have been correlated prospectively with patient response. In this study, we have used heterogeneity data for standard regimens obtained from 116 breast TCAs to set sensitivity/resistance thresholds which were then used to interpret the results from those with known clinical responses. Assay evaluability was 97% in surgical biopsies. Clinical follow-up of stage III/IV assessable disease was obtained from 27 breast tumors which were successfully tested for chemosensitivity, including 13 needle biopsies. The ATP-TCA assay predicted response correctly in 22 out of 29 (76%) tumors with clinically evaluable disease, suggesting that it is capable of predicting outcome in individual patients. Assays were performed in seven patients before and after chemotherapy using residual or recurrent tumor tissue. Four cases with initial sensitivity showed a decrease in sensitivity within 6 months of starting chemotherapy, while two others without clinical resistance were still sensitive by TCA. All nine courses of therapy given on the basis of TCA sensitivity resulted in partial or complete responses. Controlled trials of TCA-directed treatment against standardized empirical therapy should be conducted before this technology is widely adopted to assess its impact on rates of response, survival and the cost of treatment.

Original languageEnglish
Pages (from-to)630-635
Number of pages6
JournalAnti-Cancer Drugs
Volume7
Issue number6
DOIs
Publication statusPublished - Aug 1996

Fingerprint

Breast Neoplasms
Drug Therapy
Neoplasms
Needle Biopsy
Health Care Costs
Breast
Therapeutics
Survival Rate
Adenosine Triphosphate
Clinical Trials
Technology
Biopsy

Keywords

  • ATP
  • Breast carcinoma
  • Chemiluminescence
  • Chemotherapy
  • Luciferase

Cite this

Cree, I. A., Kurbacher, C. M., Untch, M., Sutherland, L. A., Hunter, E. M., Subedi, A. M. C., ... Bruckner, H. W. (1996). Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs, 7(6), 630-635. https://doi.org/10.1097/00001813-199608000-00002
Cree, Ian A. ; Kurbacher, Christian M. ; Untch, Michael ; Sutherland, Lesley A. ; Hunter, Elizabeth M. ; Subedi, Andrea M. C. ; James, Elizabeth A. ; Dewar, John A. ; Preece, Paul E. ; Andreotti, Peter E. ; Bruckner, Howard W. / Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. In: Anti-Cancer Drugs. 1996 ; Vol. 7, No. 6. pp. 630-635.
@article{bd6bde53e68d4e29a24dabd313b801a7,
title = "Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity",
abstract = "Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which fails to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from a newly developed tumor chemosensitivity assay (TCA) have been correlated prospectively with patient response. In this study, we have used heterogeneity data for standard regimens obtained from 116 breast TCAs to set sensitivity/resistance thresholds which were then used to interpret the results from those with known clinical responses. Assay evaluability was 97{\%} in surgical biopsies. Clinical follow-up of stage III/IV assessable disease was obtained from 27 breast tumors which were successfully tested for chemosensitivity, including 13 needle biopsies. The ATP-TCA assay predicted response correctly in 22 out of 29 (76{\%}) tumors with clinically evaluable disease, suggesting that it is capable of predicting outcome in individual patients. Assays were performed in seven patients before and after chemotherapy using residual or recurrent tumor tissue. Four cases with initial sensitivity showed a decrease in sensitivity within 6 months of starting chemotherapy, while two others without clinical resistance were still sensitive by TCA. All nine courses of therapy given on the basis of TCA sensitivity resulted in partial or complete responses. Controlled trials of TCA-directed treatment against standardized empirical therapy should be conducted before this technology is widely adopted to assess its impact on rates of response, survival and the cost of treatment.",
keywords = "ATP, Breast carcinoma, Chemiluminescence, Chemotherapy, Luciferase",
author = "Cree, {Ian A.} and Kurbacher, {Christian M.} and Michael Untch and Sutherland, {Lesley A.} and Hunter, {Elizabeth M.} and Subedi, {Andrea M. C.} and James, {Elizabeth A.} and Dewar, {John A.} and Preece, {Paul E.} and Andreotti, {Peter E.} and Bruckner, {Howard W.}",
year = "1996",
month = "8",
doi = "10.1097/00001813-199608000-00002",
language = "English",
volume = "7",
pages = "630--635",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott, Williams & Wilkins",
number = "6",

}

Cree, IA, Kurbacher, CM, Untch, M, Sutherland, LA, Hunter, EM, Subedi, AMC, James, EA, Dewar, JA, Preece, PE, Andreotti, PE & Bruckner, HW 1996, 'Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity', Anti-Cancer Drugs, vol. 7, no. 6, pp. 630-635. https://doi.org/10.1097/00001813-199608000-00002

Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. / Cree, Ian A.; Kurbacher, Christian M.; Untch, Michael; Sutherland, Lesley A.; Hunter, Elizabeth M.; Subedi, Andrea M. C.; James, Elizabeth A.; Dewar, John A.; Preece, Paul E.; Andreotti, Peter E.; Bruckner, Howard W.

In: Anti-Cancer Drugs, Vol. 7, No. 6, 08.1996, p. 630-635.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity

AU - Cree, Ian A.

AU - Kurbacher, Christian M.

AU - Untch, Michael

AU - Sutherland, Lesley A.

AU - Hunter, Elizabeth M.

AU - Subedi, Andrea M. C.

AU - James, Elizabeth A.

AU - Dewar, John A.

AU - Preece, Paul E.

AU - Andreotti, Peter E.

AU - Bruckner, Howard W.

PY - 1996/8

Y1 - 1996/8

N2 - Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which fails to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from a newly developed tumor chemosensitivity assay (TCA) have been correlated prospectively with patient response. In this study, we have used heterogeneity data for standard regimens obtained from 116 breast TCAs to set sensitivity/resistance thresholds which were then used to interpret the results from those with known clinical responses. Assay evaluability was 97% in surgical biopsies. Clinical follow-up of stage III/IV assessable disease was obtained from 27 breast tumors which were successfully tested for chemosensitivity, including 13 needle biopsies. The ATP-TCA assay predicted response correctly in 22 out of 29 (76%) tumors with clinically evaluable disease, suggesting that it is capable of predicting outcome in individual patients. Assays were performed in seven patients before and after chemotherapy using residual or recurrent tumor tissue. Four cases with initial sensitivity showed a decrease in sensitivity within 6 months of starting chemotherapy, while two others without clinical resistance were still sensitive by TCA. All nine courses of therapy given on the basis of TCA sensitivity resulted in partial or complete responses. Controlled trials of TCA-directed treatment against standardized empirical therapy should be conducted before this technology is widely adopted to assess its impact on rates of response, survival and the cost of treatment.

AB - Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which fails to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from a newly developed tumor chemosensitivity assay (TCA) have been correlated prospectively with patient response. In this study, we have used heterogeneity data for standard regimens obtained from 116 breast TCAs to set sensitivity/resistance thresholds which were then used to interpret the results from those with known clinical responses. Assay evaluability was 97% in surgical biopsies. Clinical follow-up of stage III/IV assessable disease was obtained from 27 breast tumors which were successfully tested for chemosensitivity, including 13 needle biopsies. The ATP-TCA assay predicted response correctly in 22 out of 29 (76%) tumors with clinically evaluable disease, suggesting that it is capable of predicting outcome in individual patients. Assays were performed in seven patients before and after chemotherapy using residual or recurrent tumor tissue. Four cases with initial sensitivity showed a decrease in sensitivity within 6 months of starting chemotherapy, while two others without clinical resistance were still sensitive by TCA. All nine courses of therapy given on the basis of TCA sensitivity resulted in partial or complete responses. Controlled trials of TCA-directed treatment against standardized empirical therapy should be conducted before this technology is widely adopted to assess its impact on rates of response, survival and the cost of treatment.

KW - ATP

KW - Breast carcinoma

KW - Chemiluminescence

KW - Chemotherapy

KW - Luciferase

UR - http://www.scopus.com/inward/record.url?scp=10244261488&partnerID=8YFLogxK

U2 - 10.1097/00001813-199608000-00002

DO - 10.1097/00001813-199608000-00002

M3 - Article

C2 - 8913430

AN - SCOPUS:10244261488

VL - 7

SP - 630

EP - 635

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 6

ER -